Prognostic significance of HE4 expression in pulmonary adenocarcinoma

We investigated the possibility of human epididymis 4(HE4) to predict survival for patients with pulmonary adenocarcinoma. One hundred and thirty-seven patients with pulmonary adenocarcinoma underwent surgery in our institute from 2000 to 2008. We used immunohistochemical analysis to determine the e...

Full description

Saved in:
Bibliographic Details
Published in:Tumor biology 2011-04, Vol.32 (2), p.265-271
Main Authors: Yamashita, Shin-ichi, Tokuishi, Keita, Hashimoto, Takafumi, Moroga, Toshihiko, Kamei, Mirei, Ono, Kiyoshi, Miyawaki, Michiyo, Takeno, Shinsuke, Chujo, Masao, Yamamoto, Satoshi, Kawahara, Katsunobu
Format: Article
Language:English
Subjects:
Adenocarcinoma - diagnosis
Adenocarcinoma - metabolism
Adenocarcinoma - mortality
Aged
beta-Defensins
Biomarkers, Tumor - metabolism
Biomedical and Life Sciences
Biomedicine
Cancer Research
Case-Control Studies
Epididymal Secretory Proteins - metabolism
Female
Gene expression
Humans
Lung cancer
Lung Neoplasms - diagnosis
Lung Neoplasms - metabolism
Lung Neoplasms - mortality
Male
Medical prognosis
Middle Aged
Prognosis
Proportional Hazards Models
Proteins
Regression Analysis
Research Article
Retrospective Studies
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We investigated the possibility of human epididymis 4(HE4) to predict survival for patients with pulmonary adenocarcinoma. One hundred and thirty-seven patients with pulmonary adenocarcinoma underwent surgery in our institute from 2000 to 2008. We used immunohistochemical analysis to determine the expression of HE4 and compared with the clinicopathological factors and survival. Serum levels of HE4 in lung adenocarcinoma were investigated by enzyme immunometric assay. Fifty-seven of 137 cases (41.6%) were HE4 positive. It was found that there was no correlation between HE4 expression by immunohistochemistry and clinicopathological factors, however, adenocarcinoma subtype was significantly associated with HE4 expression. Sera in lung adenocarcinoma were significantly higher than in healthy control. Five-year disease-free survival in the HE4-positive group (44.6%) was significantly different from that in the negative group (82.3%, p  = 0.001) by immunohistochemistry. The five-year overall survival rate was 60.1% in the HE4-positive group, as compared with 90.8% in the HE4-negative group ( p  = 0.001). In multivariate Cox regression analysis, positive HE4 protein expression was a worse prognosis factor of disease-free and overall survival (HR = 3.7, 95%CI = [1.7–8.4], p  = 0.001; HR = 5.5, 95%CI = [1.8–17.2], p  = 0.003, respectively), in addition to nodal status as a powerful value. When HE4 expression in adenocarcinoma cases except the BAC were analyzed, nodal status and HE4 expression were independent prognostic factors in disease-free and overall survivals. These data showed that HE4 expression is associated with a worse prognosis and is a possible prognostic factor of lung adenocarcinoma.
ISSN:1010-4283
1423-0380
DOI:10.1007/s13277-010-0118-5